Abstract
Background: Cervical cancer is the most common malignant tumor of female reproductive tract, with the second highest incidence in female malignant tumors and even the highest in some developing countries. Cervical cancer accounts for about 500,000 new cases worldwide each year, accounting for 5% of all new cases of cancer, more than 80% of which are in developing countries. The number of deaths of cervical cancer in China is about 53,000 per year, accounting for about 18.4% of all female malignant tumor deaths. Cervical cancer is a leading disease that endangers the health and life of women in China.
An emerging novel liquid biopsy technology called Cancer Differentiation Analysis (CDA) has been evaluated as a viable cervical cancer detection tool. As a bio-physical based marker with multi-level and multi-parameter expression features , CDA has shown the capability of detecting cervical cancer with a high degree of sensitivity and specificity.
Methods: In this study, 376 cervical cancer samples with pathological information and 922 samples from healthy female individuals were measured in a single blind test. Peripheral blood of each individual was drawn in EDTA tubes. One class of bio-physical property in blood samples was utilized for CDA tests. The CDA data were first processed using an algorithm built from data base and subsequently analyzed using SPSS. The results were shown in table 1.
Results: The average CDA values of cervical cancer and control groups were 50.99 and 36.69 (rel. units) respectively. The results indicated that cervical cancer could be significantly distinguished from the control (p < 0.001). The results indicated that CDA technology has a very good sensitivity and specificity (83.5% and 90.0%, respectively).
Conclusions: Initial results showed that CDA technology could effectively screen cervical cancer patients from healthy individuals. As a novel bio-physical based cancer detection approach with multi-level and multi-parameter expressions, CDA technology could be a potential candidate for cervical cancer detection.
- Meeting: Shenzheng New Horizons in Cancer Research. 2019.
Author(s): Hongmei Tao, Xing Tang, Yue Lin, Chris Chang Yu, Xuedong Du*
Anpac Bio-Medical Science Co., Ltd., Shanghai, China
